Anna Schandl1, Jesper Lagergren2, Asif Johar3, Pernilla Lagergren3. 1. Surgical Care Science, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden. Electronic address: anna.schandl@ki.se. 2. Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden; Division of Cancer Studies, King's College London, UK. 3. Surgical Care Science, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden.
Abstract
PURPOSE: To determine whether oesophageal cancer survivors recover in health-related quality of life (HRQOL) within 10 years of surgery. METHODS: A prospective, nationwide, population-based cohort study including 90% of all oesophageal cancer surgery patients in Sweden in 2001-2005, with follow-up through 2015. HRQOL was assessed 5 and 10 years postoperatively, using questionnaires for cancer in general (EORTC QLQ-C30) and oesophageal cancer specifically (EORTC QLQ-OES18). The HRQOL measures at 10 years after surgery were compared with the 5-year assessment. The 10-year HRQOL scores were compared with a population-based reference population (4910 individuals), individually matched for age, sex and comorbidity, by means of mean score differences with 95% confidence intervals. RESULTS: Among 616 patients, 104 (17%) survived at least 10 years. Of these, 92 (88%) responded to the HRQOL questionnaires at 5 and 10 years after surgery. Among the responders, 71% were older than 70 years. Patients did not improve in HRQOL between 5 and 10 years. Instead, the scores for 23 out of 25 HRQOL aspects declined, with clinically relevant and statistically significant deterioration in role function and appetite loss. Compared to the reference population, the 10 year-survivors had worse scores in all 25 HRQOL aspects, with significant deterioration in global quality of life, role functioning, social functioning and most symptoms. The most severe problems compared to the reference population were reflux, eating difficulties, diarrhoea and appetite loss. CONCLUSION: Patients who have undergone curative treatment for oesophageal cancer experience reduced HRQOL with persisting symptoms 10 years after surgery. Copyright Â
PURPOSE: To determine whether oesophageal cancer survivors recover in health-related quality of life (HRQOL) within 10 years of surgery. METHODS: A prospective, nationwide, population-based cohort study including 90% of all oesophageal cancer surgery patients in Sweden in 2001-2005, with follow-up through 2015. HRQOL was assessed 5 and 10 years postoperatively, using questionnaires for cancer in general (EORTC QLQ-C30) and oesophageal cancer specifically (EORTC QLQ-OES18). The HRQOL measures at 10 years after surgery were compared with the 5-year assessment. The 10-year HRQOL scores were compared with a population-based reference population (4910 individuals), individually matched for age, sex and comorbidity, by means of mean score differences with 95% confidence intervals. RESULTS: Among 616 patients, 104 (17%) survived at least 10 years. Of these, 92 (88%) responded to the HRQOL questionnaires at 5 and 10 years after surgery. Among the responders, 71% were older than 70 years. Patients did not improve in HRQOL between 5 and 10 years. Instead, the scores for 23 out of 25 HRQOL aspects declined, with clinically relevant and statistically significant deterioration in role function and appetite loss. Compared to the reference population, the 10 year-survivors had worse scores in all 25 HRQOL aspects, with significant deterioration in global quality of life, role functioning, social functioning and most symptoms. The most severe problems compared to the reference population were reflux, eating difficulties, diarrhoea and appetite loss. CONCLUSION:Patients who have undergone curative treatment for oesophageal cancer experience reduced HRQOL with persisting symptoms 10 years after surgery. Copyright Â
Authors: Sheraz R Markar; Melody Ni; Suzanne S Gisbertz; Leonie van der Werf; Jennifer Straatman; Donald van der Peet; Miguel A Cuesta; George B Hanna; Mark I van Berge Henegouwen Journal: J Clin Oncol Date: 2020-05-18 Impact factor: 44.544
Authors: Xi Luo; Qin Xie; Qiuling Shi; Yan Miao; Qingsong Yu; Hongfan Yu; Hong Yin; Xuefeng Leng; Yongtao Han; Hong Zhou Journal: Support Care Cancer Date: 2021-11-24 Impact factor: 3.603
Authors: Linlin Yang; Changxian Shen; Cory J Pettit; Tianyun Li; Andrew J Hu; Eric D Miller; Junran Zhang; Steven H Lin; Terence M Williams Journal: Clin Cancer Res Date: 2020-03-27 Impact factor: 12.531
Authors: Karin Dalhammar; Jimmie Kristensson; Dan Falkenback; Birgit H Rasmussen; Marlene Malmström Journal: BMC Cancer Date: 2022-04-21 Impact factor: 4.638
Authors: A S Borggreve; S Mook; M Verheij; V E M Mul; J J Bergman; A Bartels-Rutten; L C Ter Beek; R G H Beets-Tan; R J Bennink; M I van Berge Henegouwen; L A A Brosens; I L Defize; J M van Dieren; H Dijkstra; R van Hillegersberg; M C Hulshof; H W M van Laarhoven; M G E H Lam; A L H M W van Lier; C T Muijs; W B Nagengast; A J Nederveen; W Noordzij; J T M Plukker; P S N van Rossum; J P Ruurda; J W van Sandick; B L A M Weusten; F E M Voncken; D Yakar; G J Meijer Journal: BMC Cancer Date: 2018-10-20 Impact factor: 4.430